Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ICMT | O60725 | 9/20 | 0.52 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8977916 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL2880044 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL2880046 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL14663234 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL14596316 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL8977914 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL1741964 | 0.88 | MAPT (0.53) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL3402724 | 0.88 | MAPT (0.53) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL15527709 | 0.86 | MAPT (0.51) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL2821557 | 0.85 | MAPT (0.65) | MAPTALDH1A1MEN1TRPA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004042081-A1 | SPECIFIC HAPLOTYPES OF THE MDR1 GENE AND THEIR USE IN DIAGNOSIS AND THERAPY | CHARITÉ-UNIVERSITÄTSME DIZIN BERLIN (DE) | 2004-05-21 | — | — | WO | claimed |
| US-11479802-B2 | Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family | REGENERON PHARMACEUTICALS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20090192332-A1 | Method for Preparing Isoprenyl Cysteine Compounds and Analogs Thereof | RAPOLE KESHAVA | 2009-07-30 | — | — | US | disclosed |
| WO-2009094534-A1 | IMPROVED METHOD FOR PREPARING ISOPRENYL CYSTEINE COMPOUNDS AND ANALOGS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-5571687-A | TREATING CELLS WITH SPECIFIED COMPOUNDS TO EFFECT EXPRESSION OF MEMBRANE TRANSPORTER | DUKE UNIVERSITY (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1995033847-A1 | MODULATORS OF MULTIDRUG RESISTANCE TRANSPORTERS | DUKE UNIVERSITY (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192332-A1 | Method for Preparing Isoprenyl Cysteine Compounds and Analogs Thereof | LCAT, LIPA, GPX4 | MAPT 4815/4885ALDH1A1 2109/4885MEN1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.